XENE Xenon Pharmaceuticals Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1582313 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-100.0%
TTM net income YoY-40.0%
TTM EPS YoY-20.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-50.3%
ROA-47.4%
ROIC (approx.)-48.4%
Asset turnover0.00x
Leverage & solvency
Liabilities / assets4.5%
Debt / equity0.00x
Current ratio21.19x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.83x
Accruals ratio-8.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $7.50M | $0 | $0 | $9.43M | $18.44M |
| R&D expense | $300.94M | $210.39M | $167.51M | $105.77M | $75.46M |
| SG&A expense | $79.63M | $68.90M | $46.54M | $32.81M | $21.97M |
| Operating income | -$373.07M | -$279.30M | -$214.05M | -$129.14M | -$78.99M |
| Pretax income | -$344.89M | -$238.42M | -$182.69M | -$125.25M | -$78.89M |
| Income tax | $1.02M | -$4.09M | -$292,000 | $118,000 | -$6,000 |
| Net income | -$345.91M | -$234.33M | -$182.39M | -$125.37M | -$78.88M |
| EBITDA | -$370.53M | -$276.74M | -$211.99M | -$127.74M | -$78.09M |
| EPS (basic) | -4.36 | -3.01 | -2.73 | -2.06 | -1.77 |
| EPS (diluted) | -4.36 | -3.01 | -2.73 | -2.06 | -1.77 |
| Weighted avg. shares (diluted) | 79.25M | 77.89M | 66.89M | 60.54M | 43.63M |
| Balance sheet | |||||
| Cash & equivalents | $199.16M | $142.71M | $148.64M | $57.24M | $175.69M |
| Short-term investments | $349.72M | $484.19M | $489.44M | $534.85M | $376.09M |
| Receivables | — | $1.47M | $874,000 | $986,000 | $2.77M |
| Current assets | $560.65M | $635.26M | $644.96M | $600.30M | $559.02M |
| PP&E, net | $8.72M | $10.28M | $9.65M | $6.50M | $4.47M |
| Total assets | $633.16M | $798.14M | $964.80M | $754.15M | $572.01M |
| Current liabilities | $41.79M | $35.59M | $27.27M | $22.70M | $14.32M |
| Total liabilities | $51.40M | $43.24M | $36.88M | $32.65M | $21.97M |
| Shareholders' equity | $581.76M | $754.90M | $927.92M | $721.50M | $550.03M |
| Shares outstanding | 80.01M | 76.42M | 75.37M | 62.59M | 51.63M |
| Cash flow statement | |||||
| Operating cash flow | -$279.12M | -$181.39M | -$151.11M | -$101.03M | -$69.50M |
| Capital expenditure | $799,000 | $3.08M | $5.62M | $2.89M | $2.05M |
| Free cash flow | -$279.92M | -$184.46M | -$156.73M | -$103.92M | -$71.55M |
| Investing cash flow | $218.00M | $165.00M | -$111.39M | -$293.40M | -$246.77M |
| Financing cash flow | $117.11M | $12.13M | $353.52M | $278.47M | $447.54M |
| Depreciation & amortization | $2.54M | $2.56M | $2.06M | $1.41M | $906,000 |
| Stock-based compensation | $53.71M | $50.72M | $32.37M | $20.38M | $10.02M |
Free plan shows the latest 5 periods; Pro shows all 14 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.